Stock Price & Analysis

Based on the current price of $210.1 and analyst price targets around $212.7, ABBV stock is trading near its average target. With a positive MACD and mixed analyst sentiment, it may be a good time to hold or consider buying if you believe in the company's long-term growth.

The price prediction for ABBV stock in 2025 is $217, driven by strong performance of its key drugs and pipeline momentum. Analysts expect significant upside due to sustained growth and positive fundamentals.

The S1 support level for ABBV Stock is $199.11 ,The R1 resistant level for ABBV Stock is $212.87.

As of the end of day on 2025-04-01, the price of ABBV Stock was $206.32.

The target price for ABBV Stock according to analyst rating is 215.57, with the highest price target at 240.00 and the lowest at 190.00. Analysts have a Strong Buy rating on ABBV Stock overall.

The market cap of ABBV is $364.9B.

Analysis and Insights

ABBV may be overvalued based on its high price-to-earnings (P/E) ratio of 74.34 and price-to-book (P/B) ratio of 94.34, which are significantly higher than industry averages. The stock's forward P/E ratio of 68.91 also suggests elevated valuations compared to its earnings growth. Additionally, insider selling of $18.96 million in February raises concerns about management confidence. While ABBV's dividend yield of 3.54% is attractive, the stock's high valuation metrics and potential risks from patent expirations, such as biosimilar competition for Humira, could justify caution. Overall, ABBV appears overvalued, but its strong dividend and recent stock performance may still appeal to income-focused investors.

AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care products, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers.

Based on analyst consensus and strong product pipeline, AbbVie (ABBV) is predicted to reach $240 by 2030, driven by continued growth of Skyrizi and Rinvoq. The stock is supported by a solid fundamentals and positive technical indicators.

ABBV has a total of 50000 employees.